The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Small interfering RNA (siRNA) is a form of genetic medicine that can silence or knock out any overexpressed genes in disease.It's also called short interfering RNA.These rnas are widely used to assess the specific contributions of genes to a variety of cell phenotypes, including apoptosis, pancreatic bird signaling, cytokinesis, and cell differentiation.They are used to identify novel pathways and have a meaningful impact on the identification of targets for several diseases (such as AIDS, cancer and hepatitis) and cellular processes.The mechanism of action of siRNA involves introducing it into cells.SiRNA sequences should be designed to match the short regions of the target gene.Small interfering rnas are processed by the cell's own enzymes to eliminate the mRNA of the target gene, thereby preventing overexpression of the pathogenic gene.It is based on the natural response of cells when they detect genetic abnormalities or infections.It has some advantages over the different types of therapies currently available, such as target specificity, reduced secondary effects, and high specificity.The preclinical development duration of small interfering RNA compounds (about 15 to 24 months) is shorter than that of monoclonal antibodies (about 27 to 50 months) or other traditional small molecules (about 42 to 66 months).The shortening of preclinical stage is attributed to the rational design of RNA.The design includes mathematical algorithms assembled in software to select the most appropriate RNA sequence to silence specific genetic targets.They are usually more effective than other traditional medicines.SiRNA therapy includes liposome-based systemic therapy and nanoparticle based systemic therapy.Liposome-based systems are associated with liver-targeted pharmacokinetics, which limits the therapeutic potential of siRNA therapy to other common liver diseases, such as hepatocellular carcinoma, hepatitis, and hypercholesterolemia.
The global Small Interfering RNA (siRNA) Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Small Interfering RNA (siRNA) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Small Interfering RNA (siRNA) Therapeutics.
Report Scope
The Small Interfering RNA (siRNA) Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Small Interfering RNA (siRNA) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Small Interfering RNA (siRNA) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
- GE
- Horizon Discovery
- Thermo Scientific
- OPKO Health
- AInylam Pharmaceuticals
- Arrowhead Research
- Sanofi Genzyme
- Genecon Biotechnologies
- Arbutus Biopharma
- Silent Therapeutics
- Sylentis
Segment by Type
- Liposome Based Systemic Therapy
- Nanoparticle Based Systemic Therapy
- Other
Segment by Application
- Hospital
- Research Institutions
- Pharmaceutical and Biotechnology Companies
- Academic Institutions
- Other
By Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Netherlands)
- Asia-Pacific (China, Japan, South Korea, China Taiwan, Southeast Asia, India)
- Latin America, Middle East & Africa (Latin America, Mexico, Brazil, Turkey)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Small Interfering RNA (siRNA) Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Small Interfering RNA (siRNA) Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Liposome Based Systemic Therapy
1.2.3 Nanoparticle Based Systemic Therapy
1.2.4 Other
1.3 Market by Application
1.3.1 Global Small Interfering RNA (siRNA) Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Research Institutions
1.3.4 Pharmaceutical and Biotechnology Companies
1.3.5 Academic Institutions
1.3.6 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Small Interfering RNA (siRNA) Therapeutics Market Perspective (2019-2030)
2.2 Small Interfering RNA (siRNA) Therapeutics Growth Trends by Region
2.2.1 Global Small Interfering RNA (siRNA) Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Small Interfering RNA (siRNA) Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Small Interfering RNA (siRNA) Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Small Interfering RNA (siRNA) Therapeutics Market Dynamics
2.3.1 Small Interfering RNA (siRNA) Therapeutics Industry Trends
2.3.2 Small Interfering RNA (siRNA) Therapeutics Market Drivers
2.3.3 Small Interfering RNA (siRNA) Therapeutics Market Challenges
2.3.4 Small Interfering RNA (siRNA) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Small Interfering RNA (siRNA) Therapeutics Players by Revenue
3.1.1 Global Top Small Interfering RNA (siRNA) Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Small Interfering RNA (siRNA) Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Small Interfering RNA (siRNA) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Small Interfering RNA (siRNA) Therapeutics Revenue
3.4 Global Small Interfering RNA (siRNA) Therapeutics Market Concentration Ratio
3.4.1 Global Small Interfering RNA (siRNA) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Small Interfering RNA (siRNA) Therapeutics Revenue in 2023
3.5 Small Interfering RNA (siRNA) Therapeutics Key Players Head office and Area Served
3.6 Key Players Small Interfering RNA (siRNA) Therapeutics Product Solution and Service
3.7 Date of Enter into Small Interfering RNA (siRNA) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Small Interfering RNA (siRNA) Therapeutics Breakdown Data by Type
4.1 Global Small Interfering RNA (siRNA) Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Small Interfering RNA (siRNA) Therapeutics Forecasted Market Size by Type (2025-2030)
5 Small Interfering RNA (siRNA) Therapeutics Breakdown Data by Application
5.1 Global Small Interfering RNA (siRNA) Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Small Interfering RNA (siRNA) Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Small Interfering RNA (siRNA) Therapeutics Market Size (2019-2030)
6.2 North America Small Interfering RNA (siRNA) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Small Interfering RNA (siRNA) Therapeutics Market Size by Country (2019-2024)
6.4 North America Small Interfering RNA (siRNA) Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Small Interfering RNA (siRNA) Therapeutics Market Size (2019-2030)
7.2 Europe Small Interfering RNA (siRNA) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Small Interfering RNA (siRNA) Therapeutics Market Size by Country (2019-2024)
7.4 Europe Small Interfering RNA (siRNA) Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Small Interfering RNA (siRNA) Therapeutics Market Size (2019-2030)
9.2 Latin America Small Interfering RNA (siRNA) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Small Interfering RNA (siRNA) Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Small Interfering RNA (siRNA) Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Small Interfering RNA (siRNA) Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Small Interfering RNA (siRNA) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Small Interfering RNA (siRNA) Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Small Interfering RNA (siRNA) Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GE
11.1.1 GE Company Detail
11.1.2 GE Business Overview
11.1.3 GE Small Interfering RNA (siRNA) Therapeutics Introduction
11.1.4 GE Revenue in Small Interfering RNA (siRNA) Therapeutics Business (2019-2024)
11.1.5 GE Recent Development
11.2 Horizon Discovery
11.2.1 Horizon Discovery Company Detail
11.2.2 Horizon Discovery Business Overview
11.2.3 Horizon Discovery Small Interfering RNA (siRNA) Therapeutics Introduction
11.2.4 Horizon Discovery Revenue in Small Interfering RNA (siRNA) Therapeutics Business (2019-2024)
11.2.5 Horizon Discovery Recent Development
11.3 Thermo Scientific
11.3.1 Thermo Scientific Company Detail
11.3.2 Thermo Scientific Business Overview
11.3.3 Thermo Scientific Small Interfering RNA (siRNA) Therapeutics Introduction
11.3.4 Thermo Scientific Revenue in Small Interfering RNA (siRNA) Therapeutics Business (2019-2024)
11.3.5 Thermo Scientific Recent Development
11.4 OPKO Health
11.4.1 OPKO Health Company Detail
11.4.2 OPKO Health Business Overview
11.4.3 OPKO Health Small Interfering RNA (siRNA) Therapeutics Introduction
11.4.4 OPKO Health Revenue in Small Interfering RNA (siRNA) Therapeutics Business (2019-2024)
11.4.5 OPKO Health Recent Development
11.5 AInylam Pharmaceuticals
11.5.1 AInylam Pharmaceuticals Company Detail
11.5.2 AInylam Pharmaceuticals Business Overview
11.5.3 AInylam Pharmaceuticals Small Interfering RNA (siRNA) Therapeutics Introduction
11.5.4 AInylam Pharmaceuticals Revenue in Small Interfering RNA (siRNA) Therapeutics Business (2019-2024)
11.5.5 AInylam Pharmaceuticals Recent Development
11.6 Arrowhead Research
11.6.1 Arrowhead Research Company Detail
11.6.2 Arrowhead Research Business Overview
11.6.3 Arrowhead Research Small Interfering RNA (siRNA) Therapeutics Introduction
11.6.4 Arrowhead Research Revenue in Small Interfering RNA (siRNA) Therapeutics Business (2019-2024)
11.6.5 Arrowhead Research Recent Development
11.7 Sanofi Genzyme
11.7.1 Sanofi Genzyme Company Detail
11.7.2 Sanofi Genzyme Business Overview
11.7.3 Sanofi Genzyme Small Interfering RNA (siRNA) Therapeutics Introduction
11.7.4 Sanofi Genzyme Revenue in Small Interfering RNA (siRNA) Therapeutics Business (2019-2024)
11.7.5 Sanofi Genzyme Recent Development
11.8 Genecon Biotechnologies
11.8.1 Genecon Biotechnologies Company Detail
11.8.2 Genecon Biotechnologies Business Overview
11.8.3 Genecon Biotechnologies Small Interfering RNA (siRNA) Therapeutics Introduction
11.8.4 Genecon Biotechnologies Revenue in Small Interfering RNA (siRNA) Therapeutics Business (2019-2024)
11.8.5 Genecon Biotechnologies Recent Development
11.9 Arbutus Biopharma
11.9.1 Arbutus Biopharma Company Detail
11.9.2 Arbutus Biopharma Business Overview
11.9.3 Arbutus Biopharma Small Interfering RNA (siRNA) Therapeutics Introduction
11.9.4 Arbutus Biopharma Revenue in Small Interfering RNA (siRNA) Therapeutics Business (2019-2024)
11.9.5 Arbutus Biopharma Recent Development
11.10 Silent Therapeutics
11.10.1 Silent Therapeutics Company Detail
11.10.2 Silent Therapeutics Business Overview
11.10.3 Silent Therapeutics Small Interfering RNA (siRNA) Therapeutics Introduction
11.10.4 Silent Therapeutics Revenue in Small Interfering RNA (siRNA) Therapeutics Business (2019-2024)
11.10.5 Silent Therapeutics Recent Development
11.11 Sylentis
11.11.1 Sylentis Company Detail
11.11.2 Sylentis Business Overview
11.11.3 Sylentis Small Interfering RNA (siRNA) Therapeutics Introduction
11.11.4 Sylentis Revenue in Small Interfering RNA (siRNA) Therapeutics Business (2019-2024)
11.11.5 Sylentis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
